Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Evaluate the Safety of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy
Conditions
Interventions
Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]
Locations
2
United States
Rare Disease Research, LLC
Atlanta, Georgia, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
Start Date
October 31, 2020
Primary Completion Date
May 13, 2021
Completion Date
May 13, 2021
Last Updated
May 17, 2021
NCT07037862
NCT07160634
NCT06450639
NCT07129954
NCT06290713
NCT06925269
Lead Sponsor
Rare Disease Research, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions